Literature DB >> 22747625

Atrial fibrillation and hypertension: do new anticoagulants change the matter?

Vivencio Barrios, Carlos Escobar, Alberto Calderon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22747625      PMCID： PMC8108797          DOI： 10.1111/j.1751-7176.2012.00613.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  9 in total

1.  Anticoagulation in non-valvular atrial fibrillation: underused or wrongly used?

Authors:  Vivencio Barrios; Carlos Escobar; Alberto Calderon; Cecilia Roldan
Journal:  Am J Cardiol       Date:  2011-12-01       Impact factor: 2.778

2.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

3.  Patients with atrial fibrillation in a primary care setting: Val-FAAP study.

Authors:  Vivencio Barrios; Alberto Calderón; Carlos Escobar; Mariano de la Figuera
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2011-11-04

Review 4.  Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension.

Authors:  Athanasios J Manolis; Enrico Agabiti Rosei; Antonio Coca; Renata Cifkova; Serap E Erdine; Sverre Kjeldsen; Gregory Y H Lip; Krzysztof Narkiewicz; Gianfranco Parati; Josep Redon; Roland Schmieder; Costas Tsioufis; Giuseppe Mancia
Journal:  J Hypertens       Date:  2012-02       Impact factor: 4.844

5.  Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program).

Authors:  Paul S Chan; Thomas M Maddox; Fengming Tang; Sarah Spinler; John A Spertus
Journal:  Am J Cardiol       Date:  2011-07-26       Impact factor: 2.778

6.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Authors:  A John Camm; Paulus Kirchhof; Gregory Y H Lip; Ulrich Schotten; Irene Savelieva; Sabine Ernst; Isabelle C Van Gelder; Nawwar Al-Attar; Gerhard Hindricks; Bernard Prendergast; Hein Heidbuchel; Ottavio Alfieri; Annalisa Angelini; Dan Atar; Paolo Colonna; Raffaele De Caterina; Johan De Sutter; Andreas Goette; Bulent Gorenek; Magnus Heldal; Stefan H Hohloser; Philippe Kolh; Jean-Yves Le Heuzey; Piotr Ponikowski; Frans H Rutten
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983

7.  Apixaban in patients with atrial fibrillation.

Authors:  Stuart J Connolly; John Eikelboom; Campbell Joyner; Hans-Christoph Diener; Robert Hart; Sergey Golitsyn; Greg Flaker; Alvaro Avezum; Stefan H Hohnloser; Rafael Diaz; Mario Talajic; Jun Zhu; Prem Pais; Andrzej Budaj; Alexander Parkhomenko; Petr Jansky; Patrick Commerford; Ru San Tan; Kui-Hian Sim; Basil S Lewis; Walter Van Mieghem; Gregory Y H Lip; Jae Hyung Kim; Fernando Lanas-Zanetti; Antonio Gonzalez-Hermosillo; Antonio L Dans; Muhammad Munawar; Martin O'Donnell; John Lawrence; Gayle Lewis; Rizwan Afzal; Salim Yusuf
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

8.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

Review 9.  Why do treated hypertensives suffer strokes? An internist's perspective.

Authors:  Geza Simon
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Sep-Oct       Impact factor: 3.738
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.